Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019163 (
hepatitis B
)
38,309
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Chronic active hepatitis caused by infection with
hepatitis B
virus, a DNA virus, is a major risk factor for human hepatocellular carcinoma. Since the oncogenicity of several DNA viruses is dependent on the interaction of their viral oncoproteins with cellular tumor-suppressor gene products, we investigated the interaction between
hepatitis B
virus X protein (HBX) and human wild-type
p53 protein
. HBX complexes with the wild-type
p53 protein
and inhibits its sequence-specific DNA binding in vitro. HBX expression also inhibits
p53
-mediated transcriptional activation in vivo and the in vitro association of
p53
and ERCC3, a general transcription factor involved in nucleotide excision repair. Therefore, HBX may affect a wide range of
p53
functions and contribute to the molecular pathogenesis of human hepatocellular carcinoma.
...
PMID:Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. 813 79
Large cell liver cell dysplasia (LCD), a suggested preneoplastic change progressing to hepatocellular carcinoma, has been reported associated with alpha-1-antitrypsin deficiency which in some countries has an increased frequency of hepatocellular carcinoma. We examined the nonneoplastic liver from 13 alpha-1-antitrypsin deficiency patients for LCD and, using a labeled streptavidin-biotin technique, for immunohistochemical markers: AAT (1/200),
hepatitis B
surface (HBsAg, prediluted) and core (HBcAg, 1/400) antigens, and monoclonal (1/20) and polyclonal (1/40) mutant p53, a tumor suppressor gene. There were eight males and five females ranging from 2 mo to 76 yr (mean 40 yr). Nine livers showed cirrhosis, one chronic persistent hepatitis, one portal fibrosis, and two cholestatic hepatitis (in the two infants). The nine cases with LCD included five males and four females of mean age 46 yr (range, 17-71), eight with cirrhosis and one with portal fibrosis. Only one liver with LCD and cirrhosis had HBcAg in cirrhotic and dysplastic cells. No patient had developed hepatocellular carcinoma. All 13 livers were immunonegative for HBsAg and mutant p53, and immunopositive for AAT present in normal, cirrhotic, and dysplastic liver cells. Thus, LCD was identified in 82% of adult alpha-1-antitrypsin deficiency livers (69% including infantile patients), 89% with cirrhosis, and none with malignancy. HB expression was rarely present; serology for HB and/or hepatitis C was positive in 46% adults. Immunoreactive AAT was present in dysplastic cells.
p53
gene mutations do not appear to have a role in the pathogenesis of LCD in alpha-1-antitrypsin deficiency.
...
PMID:Liver cell dysplasia in alpha-1-antitrypsin deficiency. 815 50
Chronic hepadnavirus infection is associated with hepatocellular carcinoma (HCC) in natural hosts such as humans, woodchucks, and Beechey ground squirrels. Several possible oncogenic mechanisms have been identified, including a potential role of the hepadnavirus x (hbx) gene, which transactivates transcription regulated by certain cis-acting sequences, e.g. regulatory sequences of the
hepatitis B
virus (HBV) and heterologous regulatory sequences of other viruses and cellular genes. The oncogenic potential of hbx is suggested by the observation of HCCs in hbx transgenic mice, the oncogenic transformation of cells expressing hbx in culture, and the transactivation of oncogenes c-myc and c-jun by hbx. Cis-activation of cellular oncogenes N-myc and c-myc by viral promoter insertion has been a common finding in woodchuck hepatitis virus (WHV)-associated HCCs of woodchucks. No such cis-activation of any cellular gene has been shown in virus-associated HCCs of ground squirrels or humans. Amplification and overexpression of the c-myc gene has been a common finding in HCCs of ground squirrels, and is rare in woodchuck or human HCCs. Point mutations in the
p53
gene and allelic deletion of
p53
have been common findings in human HCCs, but have not been found in HCCs in woodchucks and have been found rarely in ground squirrels. How each of these genetic changes in the different hosts contributes to HCC remains to be determined, but apparently different changes in different HCCs of hepadnavirus-infected hosts suggest that several separate genetic events may contribute to the development of HCC. These events may differ in each host, and some may not result from a direct virus-specific mechanism. Chronic hepadnavirus infection is often associated with chronic necroinflammatory liver disease and cirrhosis, a pathologic process common to several other risk factors for HCC. This suggests that this pathologic process (necroinflammatory disease) may be hepatocarcinogenic regardless of the inciting agent. Thus hepadnavirus infection may play an important role in the development of HCC by causing chronic hepatitis and HCC with the same mechanisms by which other risk factors for HCC cause chronic necroinflammatory liver disease and HCC.
...
PMID:Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. 819 85
High levels of expression of the
p53 protein
and gene mutations have been described in adult hepatocellular carcinomas. It has been postulated that specific mutations in exon 7 may be caused by aflatoxin exposure. To determine whether
p53
mutations occur in childhood liver cancer unassociated with aflatoxin exposure or
hepatitis B
virus (HBV) infection, we have analyzed three histologically distinct tumor types. Two techniques were used to access
p53
in the tumors: (1) expression studies of the
p53 protein
were performed using the polyclonal antibody CM1 and immunohistochemistry, and (2) DNA sequencing was performed.
p53
Protein was detectable by immunohistochemistry in 10 of 15 hepatoblastomas, six of nine hepatocellular carcinomas, and one of one embryonal sarcomas. Solid phase single-stranded DNA sequencing across exons 5 through 9 showed normal sequence in all cases. These results indicate that
p53
is overexpressed in a majority of childhood liver cancers, but this abnormal
p53
expression does not seem to be caused by mutations in the
p53
gene.
...
PMID:Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. 820 Jun 35
In areas of the world where
hepatitis B
and aflatoxin ingestion are common, alterations of the
p53 tumor suppressor
gene have frequently been reported in hepatocellular carcinoma (HCC). In particular, G-to-T transversions at codon 249 of the
p53
gene have been consistently observed in hepatocellular carcinomas in China and sub-Saharan Africa. The goal of this study was to determine the frequency and relationship of
p53
gene alterations and
hepatitis B
in formalin-fixed, paraffin-embedded HCCs resected in the United States. Since immunoreactivity for
p53
correlates closely with the presence of missense mutations in the
p53
gene, we performed immunohistochemical staining with the monoclonal antibody PAb1801. Only seven of 37 cases (19%) demonstrated nuclear accumulation of
p53
gene product, in contrast to 10 of 20 cases (50%) of colon carcinoma metastatic to the liver. Staining was not observed in seven liver cell adenomas, 10 cases of focal nodular hyperplasia, or eight cases of cirrhosis. DNA was extracted from formalin-fixed paraffin sections for additional analysis with use of the polymerase chain reaction (PCR). G-to-T transversions of the third nucleotide of codon 249 were demonstrated in only four of 37 cases (11%), three of which had stained with PAb1801. Of 13 patients for whom there was information about a restriction fragment length polymorphism (RFLP) for BstUI within the fourth exon of the
p53
gene, allelic loss of
p53
was demonstrated in only two cases (15%), both of which stained with PAb1801. Because of previous reports specifically associating
hepatitis B
with
p53
mutations in HCC, we performed nested PCR for
hepatitis B
virus DNA. Five of 37 cases (14%) contained
hepatitis B
virus DNA, two of which stained diffusely for
p53
and three of which had codon 249 mutations. Our findings indicate that alterations in the
p53
gene, particularly at codon 249, are uncommon in HCCs in the United States, and when present are associated with
hepatitis B
. Since
hepatitis B
is infrequently associated with HCC in our patient population, the role of
p53
alterations in hepatocellular carcinogenesis may not be as significant as in other parts of the world where
hepatitis B
and aflatoxin are more prevalent.
...
PMID:Hepatitis B and alterations of the p53 tumor suppressor gene in hepatocellular carcinoma. 823 31
Hepatocellular carcinoma samples obtained from 59 patients at surgical resection were examined for mutations of the third base at codon 249 of the
p53
gene, using the polymerase chain reaction and oligonucleotide hybridization techniques. This point mutation, which is frequently observed in HCC cases from Southern Africa and Quidong in China, was not recognized in either 60 hepatocellular carcinomas or 53 noncancerous liver tissue samples from Japan. Thirty-four of 45 patients (75.6%) were positive for the hepatitis C virus, which was a higher rate than that for
hepatitis B
virus infection (9 of 55; 16.4%). The exposure to aflatoxin B1 was not considered to be remarkable. These results suggest that the point mutation of the third base at codon 249 is not common in Japanese patients, and it is suggested that numerous other factors affect the mutation of the
p53
gene and the development of hepatocellular carcinoma.
...
PMID:The mutation of codon 249 in the p53 gene is not specific in Japanese hepatocellular carcinoma. 825 41
Hepatocellular carcinoma (HCC) accumulates a mutation of the
p53
gene with a common substitution of nucleotide in a particular site. It is hypothesized that infection of
hepatitis B
virus (HBV) or exposure to aflatoxins could induce it. In Japan, the concentration of aflatoxins in the environment is low; however, infection of HBV and/or hepatitis C virus (HCV) is frequently seen in patients with HCC. The purpose of our studies was to determine whether these hepatoviral factors influence
p53
alterations. In our results,
p53
abnormalities, which were composed of loss of heterozygosity (LOH) and/or point mutation, were shown in 39% of patients. We postulated that they occurred at late stages in tumor growth based on the following two results. LOH analysis on
p53
showed that most of the tumor nodule consisted of two phenotypes, LOH and non-LOH cancer cells. The
p53
abnormalities correlated with the grade of cancer cell atypia which advanced with tumor growth. HBV and HCV infections were identified by polymerase chain reaction using DNA extracted from cancerous and noncancerous regions of the liver. By these methods, the patients who had been infected with either HBV or HCV showed an incidence of
p53
abnormalities (45%) higher than those infected by neither (13%). However, the detection rate of these viruses was lower in the HCC region (33%) than that in the noncancerous region (56%) in cases with mutated
p53
. The low rate of HCV detection (22%) in the HCC region with altered
p53
was attributable to these different viral detection rates. There was a difference in pattern of
p53
mutational changes in patients depending upon whether they were infected by HBV or by HCV. Two of three HBV-infected patients had a transversional change of nucleotide at the G:C site to T:A. However, in cases with HCV, four of eight patients had a transitional change of nucleotide of
p53
. These results showed that HBV and HCV infections affect carcinogenic pathways causing
p53
abnormalities independently.
...
PMID:p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. 826 44
We studied 80 hepatocellular carcinomas from three continents for
p53
gene (TP53) mutations and
hepatitis B
virus (HBV) sequences.
p53
mutations were frequent in tumors from Mozambique but not in tumors from South Africa, China, and Germany. Independent of geographic origin, most tumors were positive for HBV sequences. X gene coding sequences of HBV were detected in 78% of tumors, whereas viral sequences in the surface antigen- and core antigen-encoding regions were present in less than 45% of tumors. These observations indicate that hepatocellular carcinomas are genetically heterogeneous. Mozambican-type of hepatocellular carcinomas are characterized by a high incidence of
p53
mutations related to aflatoxins. In other tumors, the rarity of
p53
mutations combined with the frequent presence of viral X gene coding sequences suggests a possible interference of HBV with the wild-type
p53
function.
...
PMID:Genetic heterogeneity of hepatocellular carcinoma. 829 Jun 6
The weight of accumulated evidence suggests a role for the
p53 tumor suppressor
gene in the development of human hepatocellular carcinoma (HCC). Most striking is an apparent mutational specificity at codon 249 of the human gene. Aflatoxin B1 (AFB) is a liver-specific carcinogen which causes G to T substitutions. This transversion was detected at codon 249 in about 50% of the analyzed HCC tumors from African and Asian patients. In these geographic regions aflatoxin exposure and
hepatitis B
viral infection are risk factors for HCC. In contrast to the human data, no mutations at codon 249 were detected in AFB-induced tumors from non-human primates. We have analyzed the
p53
gene at the site corresponding to codon 249 of the human gene in AFB-induced preneoplastic hepatic nodules from rats. No mutations were detected in the tissues examined. Our data suggest that, at least in the rat, AFB exposure alone may not be sufficient for the specificity of
p53
mutations observed in HCC.
...
PMID:Aflatoxin B1-induced rat hepatic hyperplastic nodules do not exhibit a site-specific mutation within the p53 gene. 838 Jan 29
Mutations of the
p53
detected in human hepatocellular carcinomas suggest that its inactivation is a critical step in hepatocellular carcinogenesis. In order to test whether the expression of
p53
is compatible with the transformed phenotype of hepatoma cells, we transfected Hep 3B cell line with
p53
expression vectors. This cell line, which contains integrated
hepatitis B
virus sequences, is a good model to study whether the wild-type
p53
can function as a tumour suppressor gene in virus-related hepatocellular carcinoma. Wild-type and mutant p53 (Ala143)-expression vectors containing a neoR gene were used. The number of antibiotic-resistant colonies was six times lower after transfection with wild-type
p53
vector as compared to the mutant vector. As measured by a specific radioimmunoassay, six of eight (75%) colonies randomly selected after mutant p53 transfections expressed the transfected mutant p53 protein. In contrast, out of eight colonies from wild-type
p53
-transfections, none expressed detectable
p53 protein
. The absence of
p53 protein
was due to the selective deletion of transfected wild-type
p53
cDNA sequences. These studies demonstrate that the growth of hepatocellular carcinoma cells is not compatible with the expression of wild-type
p53
. Therefore,
p53
should be considered as a tumour suppressor gene in hepatocytes.
...
PMID:p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells. 838 Dec 23
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>